Cargando…

An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan(®) RC Early Analysis Review (CLEAR) trial

PURPOSE: To evaluate the ocular hyperemia and intraocular pressure (IOP)-lowering efficacy of bimatoprost 0.01% in subjects with elevated IOP due to primary open-angle glaucoma (POAG) or ocular hypertension (OHT) in a real-world clinical setting. SUBJECTS AND METHODS: This open-label, 12-week, obser...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crichton, Andrew C, Nixon, Donald R, Simonyi, Susan, Bhogal, Meetu, Sigouin, Christopher S, Discepola, Marino J, Hutnik, Cindy ML, Baptiste, Darryl C, Yan, David B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043802/ https://www.ncbi.nlm.nih.gov/pubmed/24920879 http://dx.doi.org/10.2147/OPTH.S46298

Ejemplares similares

An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial
por: Nixon, Donald R, et al.
Publicado: (2012)

Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study
por: Chen, Ying Ying, et al.
Publicado: (2016)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Twenty-four-hour effects of bimatoprost 0.01% monotherapy on intraocular pressure and ocular perfusion pressure
por: Tung, Jonathan D, et al.
Publicado: (2012)

Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting
por: Park, Ki Ho, et al.
Publicado: (2014)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
por: Chang-Lin, Joan-En, et al.
Publicado: (2011)

The additive effect of dorzolamide hydrochloride (Trusopt) and a morning dose of bimatoprost (Lumigan) on intraocular pressure and retrobulbar blood flow in patients with primary open-angle glaucoma
por: Stankiewicz, Andrzej, et al.
Publicado: (2010)

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% — an observational switch study
por: Deshpande, Sarita S, et al.
Publicado: (2017)

Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension
por: Xu, Kai Man, et al.
Publicado: (2022)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
por: Day, Douglas G, et al.
Publicado: (2013)

A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Stevens, Annemie, et al.
Publicado: (2016)

Late-day intraocular pressure–lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial
por: DuBiner, Harvey B, et al.
Publicado: (2014)

Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
por: Pfennigsdorf, Stefan, et al.
Publicado: (2012)

Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial
por: Zaky, Mohamed S., et al.
Publicado: (2023)

Dose–Response of Intracameral Bimatoprost Sustained-Release Implant and Topical Bimatoprost in Lowering Intraocular Pressure
por: Lee, Susan S., et al.
Publicado: (2019)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers, Jonathan S, et al.
Publicado: (2014)

A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost
por: Craven, E Randy, et al.
Publicado: (2010)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
por: Ogundele, Abayomi B, et al.
Publicado: (2010)

Proposed Mechanism of Long-Term Intraocular Pressure Lowering With the Bimatoprost Implant
por: Stamer, W. Daniel, et al.
Publicado: (2023)

Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
por: Filippelli, Mariaelena, et al.
Publicado: (2022)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
por: Campbell, Joanna H, et al.
Publicado: (2014)

Fixed-combination treatments for intraocular hypertension in Chinese patients – focus on bimatoprost-timolol
por: Fang, Yuan, et al.
Publicado: (2015)

Intraocular Pressure Effects and Mechanism of Action of Topical Versus Sustained-Release Bimatoprost
por: Lee, Susan S., et al.
Publicado: (2019)

Cytotoxicity, Mitochondrial Functionality, and Redox Status of Human Conjunctival Cells after Short and Chronic Exposure to Preservative-Free Bimatoprost 0.03% and 0.01%: An In Vitro Comparative Study
por: Petricca, Sabrina, et al.
Publicado: (2022)

Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides
por: Smid, Scott D
Publicado: (2009)

Bimatoprost in Dermatology
por: Jha, Abhijeet K., et al.
Publicado: (2018)

Effect of atropine 0.01% on progression of myopia
por: Sen, Snigdha, et al.
Publicado: (2022)

Compounded 0.01% Atropine—What's in the Bottle?
por: Richdale, Kathryn, et al.
Publicado: (2023)

Effectiveness of 0.01% atropine in anisomyopic children
por: Hussain, Azfira, et al.
Publicado: (2023)

Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial
por: Oddone, Francesco, et al.
Publicado: (2015)

P01-001 – Musculoskeletal sonography in FMF patients
por: Karadag, O, et al.
Publicado: (2013)

Effect of 0.01% Atropine on Accommodation in Myopic Teenagers
por: Li, Huixia, et al.
Publicado: (2022)

Bimatoprost in the treatment of eyelash hypotrichosis
por: Law, Simon K
Publicado: (2010)

Bimatoprost Implant: First Approval
por: Shirley, Matt
Publicado: (2020)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura, Toyoaki, et al.
Publicado: (2012)

Diurnal Intraocular Pressure with Bimatoprost/Timolol Fixed Combination versus Latanoprost/Timolol Fixed Combination in Healthy Subjects
por: Shim, Seong Hee, et al.
Publicado: (2014)

Aqueous misdirection syndrome: an interesting case presentation
por: Moinul, Prima, et al.
Publicado: (2015)

First-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension: focus on bimatoprost
por: Law, Simon K
Publicado: (2007)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_t6k3kphjkmbisg5g4eadear8u8